(Q37250382)

19 August 2017

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease (English)

1 reference

randomized controlled trial

19 August 2017

0 references

1 reference

based on heuristic

inferred from title

cognitive dysfunction

1 reference

1 reference

Jess G Fiedorowicz

4

0 references

Douglas R Langbehn

object named as

Douglas R Langbehn

5

0 references

Jane S. Paulsen

object named as

Jane S Paulsen

8

0 references

Leigh J Beglinger

1

object named as

Leigh J Beglinger

1 reference

19 August 2017

3

Henry Paulson

1 reference

19 August 2017

Williams H Adams

2

1 reference

19 August 2017

Kevin Duff

6

1 reference

19 August 2017

Anne Leserman

7

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Journal of Clinical Psychopharmacology

19 August 2017

1 reference

19 August 2017

29

1 reference

19 August 2017

5

1 reference

19 August 2017

484-487

1 reference

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Behavioural abnormalities contribute to functional decline in Huntington's disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Evidence for specific cognitive deficits in preclinical Huntington's disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Implication of right frontostriatal circuitry in response inhibition and attention-deficit/hyperactivity disorder

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

A possible pathophysiologic substrate of attention deficit hyperactivity disorder

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

White matter volume and cognitive dysfunction in early Huntington's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Rate of functional decline in Huntington's disease. Huntington Study Group

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

When does Huntington's disease begin?

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Huntington disease: Clinical care and evaluation

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

The reliability and validity of self- and investigator ratings of ADHD in adults.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Effect of donepezil on motor and cognitive function in Huntington disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Clinical markers of early disease in persons near onset of Huntington's disease.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

Unified Huntington's disease rating scale: Reliability and consistency

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806326

10.1097/JCP.0B013E3181B2AC0A

3 December 2018

Identifiers

DOI

1 reference

release_lommyidysrgdbmk7jhpj3nvdki

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lommyidysrgdbmk7jhpj3nvdki

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

19 August 2017

PubMed publication ID

19745649

1 reference